Erschienen in:
01.03.2013 | Original Article
Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers
verfasst von:
Elizabeth A. Schackmann, Diego F. Munoz, Meredith A. Mills, Sylvia K. Plevritis, Allison W. Kurian
Erschienen in:
Familial Cancer
|
Ausgabe 1/2013
Einloggen, um Zugang zu erhalten
Abstract
Women with
BRCA1 or
BRCA2 (
BRCA1/2) mutations face difficult decisions about managing their high risks of breast and ovarian cancer. We developed an online tool to guide decisions about cancer risk reduction (available at:
http://brcatool.stanford.edu), and recruited patients and clinicians to test its feasibility. We developed questionnaires for women with
BRCA1/2 mutations and clinicians involved in their care, incorporating the System Usability Scale (SUS) and the Center for Healthcare Evaluation Provider Satisfaction Questionnaire (CHCE-PSQ). We enrolled
BRCA1/2 mutation carriers who were seen by local physicians or participating in a national advocacy organization, and we enrolled clinicians practicing at Stanford University and in the surrounding community. Forty
BRCA1/2 mutation carriers and 16 clinicians participated. Both groups found the tool easy to use, with SUS scores of 82.5–85 on a scale of 1–100; we did not observe differences according to patient age or gene mutation. General satisfaction was high, with a mean score of 4.28 (standard deviation (SD) 0.96) for patients, and 4.38 (SD 0.89) for clinicians, on a scale of 1–5. Most patients (77.5 %) were comfortable using the tool at home. Both patients and clinicians agreed that the decision tool could improve patient–doctor encounters (mean scores 4.50 and 4.69, on a 1–5 scale). Patients and health care providers rated the decision tool highly on measures of usability and clinical relevance. These results will guide a larger study of the tool’s impact on clinical decisions.